Cytori Cell Research Institute,Inc. Logo

Cytori Cell Research Institute,Inc.

Develops devices and cell therapies using a patient's fat tissue to repair injury and treat disease.

3750 | T

Overview

Corporate Details

ISIN(s):
JP3426500009
LEI:
Country:
Japan
Address:
千代田区麹町2丁目3番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cytori Cell Research Institute, Inc., now operating as ADR120S, Inc., is a regenerative medicine company focused on developing novel cell therapies. The company engages in the research, development, production, and sale of medical devices and related kits for cell-based treatments. Its core technology centers on a proprietary system to extract and concentrate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue. These therapies are designed to repair injured tissue, preserve function, and address various diseases with unmet medical needs, such as osteoarthritis and diabetic foot lesions. The company aims to provide safe and effective treatment options by harnessing the potential of cellular therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 08:04
Registration Form
確認書
Japanese 8.6 KB
2025-11-14 08:03
Interim / Quarterly Report
半期報告書-第22期(2025/04/01-2026/03/31)
Japanese 194.2 KB
2025-11-07 07:42
Registration Form
確認書
Japanese 8.3 KB
2025-11-07 07:39
Annual Report
訂正有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 597.9 KB
2025-07-01 04:31
AGM Information
臨時報告書
Japanese 24.3 KB
2025-06-27 09:17
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 09:16
Annual Report
有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 946.5 KB
2025-06-27 09:16
Governance Information
内部統制報告書-第21期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-05-30 02:01
Regulatory Filings
臨時報告書
Japanese 20.1 KB
2025-02-10 08:41
AGM Information
臨時報告書
Japanese 20.5 KB
2025-01-06 08:19
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 08:05
Interim / Quarterly Report
半期報告書-第21期(2024/04/01-2025/03/31)
Japanese 190.1 KB
2024-09-24 09:07
M&A Activity
臨時報告書
Japanese 19.8 KB
2024-07-29 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.5 KB

Automate Your Workflow. Get a real-time feed of all Cytori Cell Research Institute,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cytori Cell Research Institute,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cytori Cell Research Institute,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

JW PHARMACEUTICAL Logo
South Korea
001060
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.